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Silencing of MLH1 is frequently seen in sporadic
colorectal cancers. We show here that hypoxia
causes decreased histone H3 lysine 4 (H3K4)
methylation at the MLH1 promoter via the action
of the H3K4 demethylases LSD1 and PLU-1 and
promotes durable long-term silencing in a path-
way that requires LSD1. Knockdown of LSD1 or
its corepressor, CoREST, also prevents the resil-
encing (and associated cytosine DNA methylation)
of the endogenous MLH1 promoter in RKO colon
cancer cells following transient reactivation by
treatment with the DNA methyltransferase inhibi-
tor 5-aza-20-deoxycytidine (5-aza-dC). The results
demonstrate that hypoxia is a driving force for
silencing of MLH1 and that the LSD1/CoREST com-
plex is necessary for this process. The results
reveal a mechanism by which hypoxia promotes
cancer cell evolution to drive malignant progression
through epigenetic modulation. Our findings sug-
gest that LSD1/CoREST acts as a colon cancer
oncogene by epigenetically silencing MLH1 and
also identify the LSD1/CoREST complex as a
potential target for therapy.INTRODUCTION
DNA mismatch repair (MMR) is necessary for genome stability,
and inherited defects in MMR are linked to hereditary non-
polyposis colorectal cancer (HNPCC) (Kolodner et al., 1994).
Acquired defects in MMR are seen in 15%–25% of sporadic
cancers of the colon and other sites. In most cases, the MMR
defects result from silencing of MLH1, a central factor in the
MMR pathway (Esteller et al., 1998; Herman et al., 1998).
Hypoxia is a key microenvironmental stress in solid tumors
that is associated with poor prognosis (Jubb et al., 2010). Hypox-ia also induces genetic instability in the form of elevated point
mutations (Reynolds et al., 1996), gene amplification (Young
et al., 1988), and fragile-site induction (Coquelle et al., 1998).
We have shown that BRCA1 and RAD51, in the homology-
dependent repair (HDR) pathway, and MLH1 and MSH2,
components of MMR, are transiently downregulated at the tran-
scriptional level in response to hypoxia via the action of specific
transcription factors, including p130/E2F4 and Myc/Max/Mnt/
Mad, respectively (Bindra and Glazer, 2007a, 2007b; Bindra
et al., 2004).
Epigenetic gene regulation, defined as heritable changes in
gene activity that are not caused by changes in DNA sequence,
has emerged as a major driver of the cancer phenotype. Epige-
netic regulation can be mediated by both DNA methylation and
histone modifications (Chi et al., 2010; Elsa¨sser et al., 2011).
Recently, we found that hypoxia induces epigenetic modifica-
tion and silencing of the BRCA1 promoter (Lu et al., 2011).
This raised the possibility that, more broadly, hypoxia may
play a key role in the aberrant silencing of other tumor suppres-
sor genes. To test this, we have focused on MLH1 because,
like BRCA1, it is downregulated at the transcriptional level in
response to hypoxia (Mihaylova et al., 2003) and is silenced
in sporadic tumors.
Although we had previously found that hypoxia induces tran-
sient repression of MLH1 via a shift in promoter occupancy
from activating c-Myc/Max to repressive Mad1/Max and Mnt/
Max complexes (Bindra and Glazer, 2007a), this represents a
short-term, reversible effect of hypoxia. We sought to test for a
role of hypoxia with respect to durable, long-term silencing of
MLH1 that would persist even when the hypoxic stimulus was
no longer present.
Here, we report that hypoxic stress induces durable MLH1
promoter silencing in a pathway that is dependent on the histone
demethylase LSD1. We find that LSD1, plus its corepressor,
CoREST, is necessary for MLH1 silencing. The results indicate
that hypoxia is a major driver of epigenetic silencing of MLH1
gene and suggest a mechanism by which hypoxia promotes
a mutator phenotype in cancer. The results also suggest that
hypoxia may be a key factor in the silencing of other tumor
suppressor genes in human malignancies.Cell Reports 8, 501–513, July 24, 2014 ª2014 The Authors 501
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RESULTS
Hypoxia Induces Repressive Histone Modifications at
theMLH1 Promoter
As onemeasure of epigenetic regulation ofMLH1, we probed for
hypoxia-induced histone modifications at the MLH1 promoter.
Because MLH1 is silenced in sporadic breast as well as colon
cancers (Herman et al., 1998; Naqvi et al., 2008), we examined
both a breast cancer line (MCF-7) and a colon cancer line
(SW480) to examine histone changes at the MLH1 promoter in
response to hypoxia as measured by quantitative chromatin
immunoprecipitation (qChIP). In MCF-7, hypoxia caused a
90% decrease in the levels of histone H3 lysine 4 (H3K4)
me1,2,3 (the combined mono-, di-, and trimethylated forms of
H3K4) at the MLH1 promoter after 48 hr (Figure 1A). Levels of
H3K4me2 and H3K4me3 were decreased 75% and 20%,
respectively (Figure 1A). Agarose gel images corresponding to
Figure 1A are shown in Figure S1A. A time course study revealed
that H3K4 demethylation at the MLH1 promoter is evident by
12 hr and persists through 72 hr (Figure 1B).
Histone modification at H3K9 has dual effects on gene tran-
scription: H3K9 acetylation is a marker of activation, whereas
H3K9 methylation is repressive, and it is known that hypoxia
alters H3K9 modification at various gene promoters (Chen
et al., 2006; Johnson et al., 2008). We detected a 30% decrease
in H3K9 acetylation and 70% increase in H3K9 me3 levels at
the MLH1 promoter in response to 48 hr hypoxic exposure
(Figure 1C). Over time, we found decreased H3K9 acetylation
beginning at 48 hr; however, the hypoxia-induced increase in
H3K9 methylation peaked by 12 hr, then gradually returned
back to the normoxic level by 72 hr (Figure 1D), suggesting
that increased H3K9 methylation is an early modification at the
MLH1 promoter that may be upstream of H3K9 deacetylation
and H3K4 demethylation under hypoxic stress. In SW480 cells,
we observed a 90% decrease in H3K4 me1,2,3 levels and an
80% decrease in H3K4 me2 levels at the MLH1 promoter in
response to hypoxia (Figures S1B and S1C), a pattern similar
to that in MCF-7 cells.
For comparison, we examined global H3K4 methylation levels
by western blot of total chromatin in both MCF-7 and SW480
cells in normoxia versus hypoxia, and we found that globalFigure 1. Hypoxia-Induced Histone Modifications at the MLH1 Promot
MCF-7 cells were exposed to normoxia (N) or to hypoxia at 0.01% O2 (H) for vario
determine H3K4 methylation levels and H3K9 acetylation and methylation levels
(A) Decreased H3K4 methylation levels at the MLH1 promoter in response to
methylation forms. Relative promoter occupancies (percent [%] input) are shown w
signal is set as 100% (not depicted in graphs) for each assay.
(B) Time course assay of H3K4 methylation changes at theMLH1 promoter. MCF
analysis. Promoter occupancy levels are expressed as the fold change relative to
SEs. Significant differences were identified as *p < 0.05 or **p < 0.01 compared
(C) Hypoxia increases H3K9 methylation and decreases H3K9 acetylation at t
methylation (right) levels at theMLH1 promoter after 48 hr of normoxia or hypoxia
error bars calculated as above.
(D) Time course of hypoxia-induced H3K9 acetylation (left) and methylation (rig
normoxia or hypoxia for the indicated times, and H3K9 acetylation and methylat
(E) Time course of MLH1 expression at the protein level determined by western blo
the indicated times and were collected for western blot analysis.
(F) Time course of MLH1 mRNA expression by quantitative real-time PCR ana
corresponding normoxic control cells at each time point.H3K4 methylation levels are not decreased (Figure S2). Hence,
the decreased methylation of H3K4 seen at the MLH1 promoter
does not simply reflect global changes in H3K4 methylation
(because overall levels of H3K4 methylation do not go down).
Rather, it likely reflects promoter-specific effects. However,
this does not mean that the effect is unique to the MLH1 pro-
moter because many other sites may be targeted for H3K4
demethylation in hypoxia. In fact, we previously observed
hypoxia-induced H3K4 demethylation at the BRCA1 promoter
(Lu et al., 2011). In that same work, we also found increased
H3K4 methylation at the VEGF promoter, showing that hypox-
ia-mediated H3K4 methylation changes can vary from gene to
gene reflecting specific differences in regulation.
Next, we evaluatedMLH1 protein andmRNA levels bywestern
blot and quantitative real-time PCR in theMCF-7 and SW480 cell
lines. We found that MLH1 protein levels and mRNA levels are
both reduced in conjunction with the changes in chromatin
marks at the promoter in response to hypoxia in MCF-7 cells
(Figures 1E and 1F) and in SW480 cells (Figures S1D and S1E).
To provide an in vivo correlation with the reduced MLH1
expression in hypoxic cells, we examined SW480 xenograft tu-
mors in nude mice. By immunofluorescence on tumor sections,
we found that MLH1 expression is inversely correlated with
expression of carbonic anhydrase IX (CAIX), a marker of hypoxia
(Figure S3A). Although this analysis reflects just one snapshot in
time within the tumor and therefore cannot demonstrate long-
term silencing, it does provide a useful in vivo data point corrob-
orating the influence of hypoxia on MLH1 expression.
We also tested for the presence of cytosine methylation in
SW480 cells after short-term hypoxia as in Figure 1. In prior
work, we had found no cytosine methylation at the MLH1 pro-
moter after just 48 hr of hypoxia (Mihaylova et al., 2003), and
we had the same results again using two different methods (Her-
man et al., 1998; Xiong and Laird, 1997) (data not shown). Given
the very short-term nature of this exposure, the lack of detect-
able DNA methylation is not surprising.
Because MLH1 plays a major role in DNA MMR, a decrease in
MLH1 levels would be predicted to yield an increase in genetic
instability. We had previously shown that decreased MLH1
expression in hypoxia confers a mutator phenotype, charac-
terized by reporter transgene mutagenesis (Mihaylova et al.,er, Accompanied by Downregulated MLH1 Expression
us times. Cells were collected for qChIP analyses using specific antibodies to
at the MLH1 promoters.
48 hr of hypoxia. Specific antibodies were used to determine specific H3K4
ith error bars based on SEs calculated from at least three replicates. The input
-7 cells placed under hypoxia were collected at the indicated times for qChIP
normoxia, based on three independent ChIP assays, with error bars based on
to normoxic levels.
he MLH1 promoter. qChIP analysis is shown of H3K9 acetylation (left) and
exposure. Relative promoter occupancies (percent [%] input) are shown with
ht) at the MLH1 promoter by qChIP analysis. MCF-7 cells were exposed to
ion levels at the MLH1 promoter were analyzed as above.
t analysis in MCF-7 cells. Cells were exposed to normoxia (N) or hypoxia (H) for
lysis. mRNA levels are expressed as the fold change relative to those of the
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Figure 2. The Histone Demethylases, LSD1 and PLU-1, and the LSD1 Partner, CoREST, Together Mediate Hypoxia-Induced H3K4
Demethylation at the MLH1 Promoter
SW480 cells with LSD1 knockdown, PLU-1 knockdown, or double knockdown of both LSD1 and PLU-1 were established using lentiviral shRNA constructs
targeting LSD1 or PLU-1. Control cells were transduced with a lentiviral expression construct for a GFP shRNA.
(A) Western blot analyses to determine LSD1 and PLU-1 expression levels in the SW480-GFPsh, SW480-LSD1sh, SW480-PLU-1sh, and double-knockdown
SW480-LSD1-PLU-1sh cells under normoxic and hypoxic conditions.
(B) qChIP analyses of H3K4 methylation levels at the MLH1 promoter following 48 hr exposure to normoxia or hypoxia in SW480-GFPsh cells, SW480-LSD1sh
cells, SW480-PLU-1sh cells, and double-knockdown SW480-LSD1-PLU-1sh cells (indicated as SW-L1P2). Promoter occupancy levels are expressed as the fold
change relative to the normoxic control SW480 GFPsh cells. SEs are indicated.
(legend continued on next page)
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2003). To further confirm this, we assayed for the impact of hyp-
oxia on the stability of a (CA)29 dinucleotide insert within the
b-galactosidase gene in an episomal vector. Frameshift muta-
tions can put b-galactosidase back into frame, as measured by
b-galactosidase activity in cell lysates. We found that hypoxia
causes an increase in b-galactosidase activity and that this
increase can be suppressed by forced expression of MLH1 via
a heterologous promoter (Figure S3B). In addition, trichostatin
A (TSA), a histone deacetylase (HDAC) inhibitor that was previ-
ously found to prevent MLH1 mRNA downregulation in short-
term hypoxia (Mihaylova et al., 2003), was also able to attenuate
the increased mutator phenotype (Figure S3B). These data
confirm prior findings that hypoxia induces mutagenesis and
provide a further link to altered MLH1 levels.
The Lysine-Specific Demethylases, LSD1 and PLU-1,
Mediate Hypoxia-Induced H3K4 Demethylation at the
MLH1 Promoter
In prior work, we demonstrated that LSD1 mediates repression
of BRCA1 and RAD51 in response to hypoxia (Lu et al., 2011).
Therefore, we tested whether LSD1 is also required for H3K4
demethylation at the MLH1 promoter in response to hypoxia.
We established SW480 subclones with stable small hairpin
RNA (shRNA) knockdown of LSD1, SW480LSD1sh, along with
a control line with shRNA targeting of GFP (Figure 2A). The cells
were exposed or not to hypoxia for 48 hr and analyzed for H3K4
methylation status. We found that knockdown of LSD1 partially
attenuated hypoxia-induced decreases in H3K4 methylation
levels at theMLH1 promoter (Figure 2B). However, these effects
were less than we expected based on prior work with BRCA1
and RAD51, and so we went on to analyze the impact of other
histone demethylases. Because it is induced by hypoxia, we
focused on the possible role of PLU-1 (Lu et al., 2011; Xia
et al., 2009). As above, we established stable shRNA knockdown
of PLU-1 in an SW480 subclone (Figure 2A). Although PLU-1 is
normally expressed at low baseline levels in SW480 cells, we
confirmed that it is inducible in response to hypoxia and that
this induction is blocked in the PLU-1 shRNA-expressing line
(Figure 2A). Using these cells, we found that knockdown of
PLU-1 also partially attenuates hypoxia-induced H3K4 demethy-
lation at theMLH1 promoter (Figure 2B), with a level of attenua-
tion similar to that in SW480 LSD1sh cells.
Because knockdown of LSD1 and PLU-1 individually showed
partial reduction of hypoxia-induced H3K4 demethylation, we
tested simultaneous knockdown of both (Figure 2A). We found
that the dual knockdown in SW480 cells yielded greater inhibi-
tion of hypoxia-induced H3K4 demethylation than in the single
knockdown lines (Figure 2B): in the comparison of cells with dou-
ble knockdown of LSD1 and PLU-1 to GFPsh control cells in
hypoxia, the p values are p = 0.011 for H3K4-me1,2,3 levels
and p = 0.015 for H3K4-me2 levels. Similar results were seen(C) Quantitative real-time PCR analysis ofMLH1mRNA levels in SW480 GFPsh, S
normoxic or hypoxic exposure. mRNA levels are expressed as the fold change r
(D) Western blot analysis of MLH1 protein levels in the same cell lines as in (C) a
(E) CoREST also plays a role in hypoxia-inducedH3K4 demethylation at theMLH1
at theMLH1 promoter following 48 hr exposure to normoxia or hypoxia in the SW4
levels are expressed as the fold change relative to the normoxic SW480 GFPshin MCF7 cells (data not shown). These results indicate that
LSD1 and PLU-1 are nonredundant and that both are involved
in hypoxia-induced H3K4 demethylation at the MLH1 promoter.
This result differs from our previous work implicating LSD1, by
itself, in hypoxia-induced H3K4 demethylation at the BRCA1
and RAD51 promoters (Lu et al., 2011); PLU-1 was not seen to
play any role in that prior work.
We next examined the changes in MLH1 expression at both
the protein and mRNA levels in response to hypoxia in control
SW480 GFPsh cell line compared to LSD1 knockdown cells
(SW480 LSD1sh), PLU-1 knockdown cells (SW480 PLU-1sh),
or double-knockdown cells (SW480 LSD1sh-PLU-1sh). We
found that knockdown of either LSD1 or PLU-1 alone did not
have statistically significant effects on the hypoxia-induced
reduction in MLH1 mRNA (Figure 2C; p = 0.12 in comparison
between LSD1 knockdown to GFPsh control, and p = 0.09
in comparison of PLU-1 knockdown to GFPsh control) or pro-
tein levels (Figure 2D). However, double knockdown of LSD1
and PLU-1 did substantially prevent the downregulation of
MLH1 by hypoxia at both the mRNA (Figure 2C; p = 0.0053)
and protein levels (Figure 2D), in keeping with the ChIP data
(Figure 2B).
To further probe the mechanism of the MLH1 downregulation,
we tested whether hypoxia induces LSD1 occupancy at MLH1
promoter. ChIP assays were performed from SW480 cells
following exposure to normoxia or hypoxia. We found almost
no LSD1 binding to the MLH1 promoter in normoxic cells; how-
ever, in hypoxic cells, we observed increased LSD1 binding to
the MLH1 promoter (Figure S4). The ACTB-2 promoter was
used as a positive control for LSD1 binding (Figure S4).
The demethylase activity of LSD1 requires its heterodimer
partner, CoREST (Lee et al., 2005; Shi et al., 2005), and so
we examined the role of CoREST in the hypoxia-induced his-
tone modifications at the MLH1 promoter. In SW480 cells with
shRNA-mediated knockdown of CoREST (SW480 CoRESTsh),
ChIP assays revealed that CoREST knockdown, like LSD1
knockdown, attenuated hypoxia-induced H3K4 demethylation
at the MLH1 promoter in SW480 cells (Figure 2E).
Hypoxia InducesMLH1 Promoter Silencing in a Pathway
Dependent on LSD1
Next, we sought to test whether hypoxia can induce the durable,
long-term silencing of the MLH1 promoter, an endpoint distinct
from short-term, reversible repression. We engineered an assay
system to select for cells in which theMLH1 promoter had under-
gone silencing. We used a construct containing the 1.7 kbMLH1
promoter driving the expression of the thymidine kinase (TK)
gene fused to the blasticidin-resistance (BlastR) gene (Figure 3A).
This construct was transfected into RKO cells and the resultant
stable cell line, designated RKO MLH1p-TK-BlastR, and was
resistant to blasticidin but sensitive to ganciclovir (GCV),W480 LSD1sh, SW480 PLU-1sh, and SW480 LSD1-PLU-1sh cells after 48 hr of
elative to normoxic control SW480 GFPsh cells.
fter 48 hr of normoxic or hypoxic exposure.
promoter in SW480 cells. qChIP analyses are shown of H3K4methylation levels
80 GFPsh cells compared to the SW480 CoRESTsh cells. Promoter occupancy
cells, based on three independent ChIP assays with error bars based on SEs.
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Figure 3. Hypoxia Induces Silencing of the
MLH1 Promoter in a Pathway Dependent
on LSD1
(A) Schematic of the MLH1-TK-BlastR dNheI
pDisplay construct used to select for clones un-
dergoing MLH1 promoter silencing.
(B) Frequency of GCV-resistant clones (indicative
of silencing of MLH1-TK-BlastR expression)
following exposure of RKO cells to normoxia or
hypoxia (1% O2) for the indicated number of days.
Selection in the presence of GCV was performed
under normoxic conditions for 10 additional days.
Error bars represent SEs from three replicates.
(C) Image of representative cell culture wells
showing differential GCV-resistant colony forma-
tion following growth in normoxia or hypoxia and
subsequent GCV selection. Contl, control.
(D) Treatment of MLH1-silenced clones with the
DNA methylation inhibitor, 5-aza-dC, reactivates
the silenced MLH1 promoters to yield GCV
sensitivity (due to reactivated TK expression) and
BlastR (due to BlastR expression). GCV-resistant
clones induced by hypoxia were pooled and
treated with DMSO, 0.2 mm5-aza-dC, or 0.3 mm5-
aza-dC for 48 hr. Colony formation in the presence
of GCV (black bar) or blasticidin (checkered bar)
was quantified relative to the DMSO control as
shown.
(E) Knockdown of LSD1 inhibits the hypoxia-
induced silencing of the MLH1 promoter
construct. RKO cells containing the MLH1-TKR-
BlastR construct and expressing shRNA to either
GFP or LSD1 were exposed to normoxia or 1%O2
for 35 days and then selected in GCV for 10
additional days under normoxic conditions. The
frequency of the resulting GCV-resistant clones
indicative of MLH1 promoter silencing is shown.reflecting expression of both selectable markers in the expres-
sion cassette. To test whether hypoxia could silence the MLH1
promoter in this construct, the RKO MLH1p-TK-BlastR cells
were exposed to hypoxia for 10, 15, 25, or 35 days at a moderate
hypoxia level of 1%O2. The hypoxia-exposed cell populations at
each time point (along with normoxic control cells grown in par-
allel) were subjected to selection (under normoxic conditions) for
GCV resistance (and therefore lack of TK expression) by incuba-
tion for 10 days inmedium containing GCV, which is toxic to cells
with functional TK. GCV-resistant clones represent cells in which
the MLH1 promoter has been silenced. We found that as the
duration of hypoxic exposure increased, so did the frequency
of GCV-resistant colonies (Figure 3B). After 35 days of exposure
to 1% O2, the cells gave rise to GCV-resistant clones at a fre-
quency of about 0.024%, 8-fold more than the background
frequency in cells grown in normoxic conditions (Figures 3B
and 3C). Consistent with promoter silencing in the expression
cassette, the clones were blasticidin sensitive and lacked tran-
scription from the cassette but still retained the construct (data506 Cell Reports 8, 501–513, July 24, 2014 ª2014 The Authorsnot shown). Beyond the 10-day selection
period, we confirmed that the silencing
was durable because randomly selected
clones were grown in normoxic condi-tions for over 4 months and still showed silencing of the MLH1
promoter (data not shown). These results show that hypoxia
can enforceMLH1 promoter silencing and that the silencing per-
sists even after the cells are no longer in hypoxic conditions.
Because RKO cells are a colon cancer cell line in which the
endogenous MLH1 gene is silenced, we considered the
possibility that they might have a special susceptibility to
silencing of the MLH1 promoter in the MLH1p-TK-BlastR re-
porter construct. Therefore, we also tested for hypoxia-induced
silencing of the MLH1p-TK-BlastR construct in SW480 cells
because they are a colon cancer cell line without endogenous
MLH1 silencing. The stable transfectant cell line, designated
SW480MLH1p-TK-BlastR, was exposed to normoxia or hypoxia
(0.5% O2) for 5 weeks. We then selected for GCV-resistant cells
as a measure of MLH1 promoter silencing, as above for RKO
cells. We observed hypoxia-induced GCV-resistant SW480 cells
(Figure S5), indicating that hypoxia-mediated silencing of the
MLH1p-TK-BlastR construct had occurred in the SW480 cells
and showing that this effect is generalizable to other cell lines
besides RKO. Although the frequency of silenced clones in
SW480 was lower than in RKO, it was still substantially more
than the background in the normoxic cells, and this difference
was statistically significant (p = 0.019).
Because gene silencing is frequently associated with DNA
hypermethylation at promoter CpG sites (including in the MLH1
promoter in sporadic colon cancers), we probed the role of
DNA methylation at cytosines in the observed hypoxia-induced
MLH1 silencing. We asked whether treatment with the DNA
methyltransferase inhibitor, 5-aza-20-deoxycytidine (5-aza-dC),
could reactivate the silenced MLH1 promoter in the hypoxia-
induced GCV-resistant cells. Reactivation of the silenced
MLH1 promoter would be expected to yield TK and BlastR
gene expression so that cells would become sensitive to GCV
and resistant to blasticidin. We pooled the GCV-resistant
RKO MLH1p-TK-BlastR clones and exposed the pooled cells
to 5-aza-dC for 48 hr. Following a dose of 0.3 mM 5-aza-dC,
we observed that approximately 30% of the cells had become
sensitive to GCV again (Figure 3D), and a corresponding number
(approximately 25%) had simultaneously become resistant to
blasticidin (Figure 3D). In contrast, in the DMSO-treated control
group, essentially all of the cells remained resistant to GCV
and sensitive to blasticidin (Figure 3D). These results demon-
strate that hypoxia-inducedMLH1 promoter silencing is partially
reversible with 5-aza-dC treatment and, thus, was associated
with DNA methylation. However, in the absence of 5-aza-dC
treatment, the silencing is otherwise stable because, as noted
above, it persists long after the cells are returned to normoxic
conditions.
To test the putative role of LSD1 in the hypoxia-inducedMLH1
silencing, we established a subline of the RKO MLH1p-TK-
BlastR cells with stable knockdown of LSD1 and exposed the
cells to hypoxia (1% O2) for 35 days. We found that LSD1
knockdown substantially inhibited the hypoxia-induced MLH1
silencing, reducing the frequency to less than one-fifth of that
in the control RKO MLH1p-TK-BlastR cells containing a GFPsh
vector (Figure 3E). (There was a small reduction in silenced
clones in normoxia by LSD1 knockdown compared to GFP
knockdown, but this was not statistically significant: p =
0.367.) The substantial reduction in silencing in hypoxia by
LSD1 knockdown was not simply due to LSD1 knockdown
affecting plating efficiency. LSD1 knockdown, by itself, had no
effect on colony formation by cells under normoxic conditions
and only a minimal effect under hypoxic conditions, with less
than a 10% reduction (data not shown). Importantly, this small
effect on colony formation was taken into account in analyzing
the results because the data presented in Figure 3E are normal-
ized to the plating efficiency control. It should be mentioned that
there was a 20% reduction in the rate of cell proliferation in the
LSD1 knockdown cell line, compared to the GFPsh control cell
line (as judged by serial cell counts; data not shown), consistent
with reports showing that LSD1 inhibition can impact tumor cell
growth (Ding et al., 2013; Huang et al., 2009). But this did not
translate into an effect on clonogenicity as measured by the
frequency of ultimate colony formation from a specific number
of seeded cells, which was minimally impacted. Overall, these
results indicate that LSD1 is necessary for MLH1 silencing in
response to hypoxia.LSD1 and Its Corepressor, Co-REST, Mediate MLH1
Resilencing following Reactivation by 5-aza-dC
Treatment in RKO Cells
Inhibition of LSD1 by small molecules or knockdown by RNAi
can reactivate certain aberrantly silenced genes in cancer cell
lines, in particular secreted frizzled-related proteins (SFRPs)
(Huang et al., 2007; Wang et al., 2011). Consequently, we asked
whether knockdown of LSD1 (or other lysine demethylases)
might similarly reactivate silenced MLH1 in RKO cells. We
established shRNA-expressing cell lines by transducing lentiviral
expression constructs for shRNAs targeting LSD1, RBP2, or
PLU-1 in RKO cells, designated as RKO LSD1sh cells, RKO
RBP2sh cells, and RKO PLU-1sh cells, respectively. In contrast
to the published results for the SFRP genes,MLH1 could not be
reactivated with LSD1 knockdown (Figure S6; compare lanes
without 5-aza-dC or TSA treatment). There was also noMLH1 re-
activation seen with knockdown of PLU-1 or RBP2 (Figure S6).
However, treatment of the RKO cells with 5-aza-dC at 5 mm for
72 hr was able to reactivate MLH1 expression (Figure S6),
consistent with other published work by Fahrner et al. (2002).
Interestingly, there was no additional increase in MLH1 expres-
sion when 5-aza-dC treatment was combined with knockdown
of any of the histone demethylases or treatment with TSA, a
HDAC inhibitor.
Although 5-aza-dC treatment of cancer cells in culture can re-
activate DNA-hypermethylated genes, gene silencing is typically
reestablished once cells are released from 5-aza-dC inhibition
(McGarvey et al., 2006). Specifically, in RKO cells, MLH1 can
be reactivated by 5-aza-dC treatment, but it becomes silenced
again once the agent is removed (McGarvey et al., 2006). We
sought to determine what roles, if any, LSD1 or PLU-1 might
play in theMLH1 resilencing after removal of 5-aza-dC treatment
in RKO cells. Again, stable H3K4 demethylase knockdown cell
lines, RKO LSD1sh and RKO PLU-1sh, were tested in compari-
son to RKO GFPsh as a control (Figure 4C). Cells were treated
with 5-aza-dC with or without TSA for 8 days and then placed
in regular growth conditions for up to 47 days. Immediately after
the 8-day exposure to 5-aza-dC, all cell lines showed re-expres-
sion of MLH1 at similar protein levels (Figure 4A). The addition of
TSA did not produce any additional increased expression. In
keeping with prior reports, after the cells were removed from
5-aza-dC and grown in standard conditions for 27 days, MLH1
became undetectable at the protein level in the control cell
line, RKO GFPsh cells, consistent with resilencing of the gene
(Figure 4A). However, MLH1 expression was maintained in
RKO LSD1sh cells. In the RKO PLU-1sh cells, resilencing of
MLH1 did eventually occur by day 47, but this process was de-
layed and attenuated at earlier time points compared to controls
(Figure 4A). The results indicate that knockdown of LSD1 can
inhibit MLH1 resilencing in RKO cells and that knockdown of
PLU-1 can partially disrupt and slow MLH1 resilencing.
We next examined if the resilencing of the MLH1 promoter in
the RKO cells would be influenced by hypoxia. RKO GFPsh,
RKO LSD1sh, and RKO PLU-1sh cells were treated with 5-
aza-dC for 8 days in normoxia as the same as above (Figure S7A).
After release from 5-aza-dC, the cells were maintained either in
normoxic or hypoxic conditions (0.5%O2) for the indicated times
(Figure S7B). Hypoxia exposure to the RKO cells with reactivatedCell Reports 8, 501–513, July 24, 2014 ª2014 The Authors 507
Figure 4. LSD1 and CoREST Are Required
forMLH1Resilencing in RKOCells following
Reactivation by Transient 5-aza-dC Expo-
sure
RKO GFPsh cells, RKO LSD1sh cells, RKO PLU-
1sh cells, and RKO CoRESTsh cells were treated
with 5-aza-dC at 5 mm for 8 days. The cells were
then placed in standard conditions for 42 addi-
tional days. MLH1 expression was analyzed at the
indicated times.
(A) Western blot analyses to determine MLH1
expression levels in RKO GFPsh cells, RKO
LSD1sh cells, and RKOPLU-1sh cells immediately
after 8 days of 5-aza-dC treatment (indicated as
D-8) or after replacement in standard medium
without 5-aza-dC for 27 days (indicated as R-27),
37 days (indicated as R-37), or 47 days (indicated
as R-47).
(B) Western blot analyses to determine MLH1
expression levels in RKO GFPsh cells and
RKO CoRESTsh cells immediately after 5-aza-dC
treatment for 8 days (indicated as D-8) or after
replacement in standard medium for 15 days
(indicated as R-15), 28 days (indicated as R-28), or
38 days (indicated as R-38).
(C) Western blot analyses to determine LSD1
expression levels in RKO GFPsh, RKO LSD1sh,
and RKO CoRESTsh cells.
(D) Western blot analyses to determine CoREST
expression levels in RKO GFPsh and RKO
CoRESTsh cells.MLH1 promoters did not increase the rate at which resilencing
occurred. As above, MLH1 resilencing was blocked by LSD1
knockdown under both normoxic and hypoxic conditions (Fig-
ure S7B), and again, PLU-1 knockdown delayed the resilencing
under both conditions (Figure S7B).
The demethylase activity of LSD1 requires the CoREST pro-
tein (Lee et al., 2005; Shi et al., 2005), and so we examined
whether CoREST participates with LSD1 in mediating MLH1
silencing. We established stable CoREST knockdown in RKO
cells (RKO CoRESTsh cells; Figure 4D.) and tested the impact
of CoREST on MLH1 silencing (Figure 4B). Similar to what we
observed in the LSD1sh cell line (Figure 4A), we found that
knockdown of CoREST, by itself, did not reactivate the silenced
MLH1 (see lanes in Figure 4Awithout 5-aza-dC treatment). How-
ever, knockdown of CoREST did blockMLH1 resilencing in RKO508 Cell Reports 8, 501–513, July 24, 2014 ª2014 The Authorscells after 5-aza-dC removal (Figure 4B),
similar to the effect of LSD1 knockdown
(Figure 4A). Interestingly, we observed
that knockdown of CoREST resulted in
partial knockdown of LSD1 (Figure 4C),
consistent with a prior report showing
that CoREST protects LSD1 from degra-
dation (Shi et al., 2005). Hence, some of
the effects of CoREST knockdown may
also reflect the consequent decrease in
LSD1 levels. Nonetheless, these results
indicate that the LSD1/CoREST complex
is critical for establishment of MLH1silencing but that knockdown of either of the components of
this complex is not sufficient, by itself, to reactivate the gene
once it has been silenced. The additional factors required for
stable MLH1 reactivation remain to be determined.
H3K4 Demethylation Occurs at the MLH1 Promoter
during Resilencing in RKO Cells and Is Mediated by
LSD1
DNA methyltransferase inhibitors not only directly inhibit
DNA methylation but also can influence histone modifications
(Fahrner et al., 2002; McGarvey et al., 2006). We conducted
qChIP analyses to evaluate the dynamics of histone marks
upon 5-aza-dC-mediated activation ofMLH1 and then during re-
silencing following cessation of 5-aza-dC treatment, as well as to
probe the role of LSD1 in this process. Consistent with previous
Figure 5. The Histone Demethylase, LSD1,
Mediates H3K4 Demethylation at the MLH1
Promoter during MLH1 Silencing in RKO
Cells
RKO GFPsh and RKO LSD1sh cells were treated
with 5-aza-dC at 5 mm for 8 days. The cells were
then replaced in normal culture medium for 28
additional days. ChIP analyses were performed to
determine H3K4 methylation and H3K9 acetyla-
tion levels at the MLH1 promoter at the indicated
times.
(A) Agarose gel image of ChIP analyses of H3K4
methylation and H3K9 acetylation levels at the
MLH1 promoter following 8 days (D-8) of 5-aza-dC
treatment in RKO GFPsh cells and RKO LSD1sh
cells. PCR amplification products corresponding
to the MLH1 promoter region are shown.
(B) Quantification of H3K4 methylation and H3K9
acetylation levels by real-time PCR at the MLH1
promoter under the same conditions as in (A).
Relative promoter occupancies (percent [%] input)
are shownwith error bars based on SEs calculated
from at least three replicates.
(C) Agarose gel image of ChIP analyses of H3K4
methylation and H3K9 acetylation levels at the
MLH1 following 28 days recovery (R-28) after 5-
aza-dC treatment in RKO GFPsh cell line versus
RKO LSD1sh cell line.
(D) Quantification of H3K4 methylation and H3K9
acetylation levels by real-time PCR at the MLH1
promoter in the same condition as (C).work by Fahrner et al. (2002), we found increased H3K9 acetyla-
tion and increased H3K4 methylation atMLH1 immediately after
5-aza-dC treatment in both the RKO GFPsh and RKO LSD1sh
cells (Figures 5A and 5B). Following release from 5-aza-dC and
growth in standard conditions for 28 days, qChIP analyses re-
vealed that, in the control RKO GFPsh cells, H3K9 acetylation
and H3K4 methylation returned back to the levels seen in cells
that were not treated with 5-aza-dC (Figures 5C and 5D); how-
ever, in the RKO LSD1sh cells, the levels of H3K4 methylation
were still elevated at the MLH1 promoter (Figures 5C and 5D;
p = 0.008 for H3K4-me1,2,3 levels and p = 0.001 for H3K4-
me2 levels). TheH3K9 acetylation levels also appeared to remain
elevated (Figures 5C and 5D), but the differences in H3K9 acet-
ylation levels did not reach statistical significance (p = 0.07).
Nonetheless, the H3K4 modification patterns are consistent
with the MLH1 protein expression data in Figure 4A and show
that LSD1 serves as a key regulatory factor to enforce repressive
histone marks during MLH1 resilencing.
LSD1 and CoREST Are Required for MLH1 Promoter
DNA Methylation after Release from 5-aza-dC
Treatment
To test whether the LSD1/CoREST complex impactsMLH1 pro-
moter DNA remethylation after release of RKO cells from 5-aza-
dC, we used a real-time PCR-based assay to quantify MLH1
promoter DNA methylation levels following bisulfite-induced
conversionof unmethylatedC intoU, leavingmethylatedC intact.
We treated RKO GFPsh cells, RKO LSDsh cells, and RKO
CoRESTsh cells with 5-aza-dC for 8 days, followed by release
into standard growth medium. Immediately after the 8-day treat-ment with 5-aza-dC, MLH1 promoter DNA methylation levels
in all three cell lines (RKO GFPsh, RKO LSD1sh, and RKO
CoRESTsh) were decreased to about 50%of untreated controls,
as expected. In the RKO GFPsh cells, the MLH1 promoter DNA
methylation levels gradually returned back to pretreatment levels
by 30 days after release (Figures 6A and 6D). In contrast, in both
the LSD1 and CoREST knockdown cell lines, MLH1 promoter
DNA methylation levels remained low even 30 days after release
from 5-aza-dC (Figures 6B–6D; p = 0.011 and p = 0.017 for LSD1
knockdown and CoREST knockdown RKO cells, respectively, in
comparison to control GFPsh cells at 30 days posttreatment).
These results strongly suggest that histonemodification patterns
mediated by LSD1 and CoREST are needed for remethylation of
theMLH1 promoter during the resilencing process.
The Repressive Complexes Max/Mad1 and Max/Mnt
Pathway Are Not Required for Hypoxia-Induced Histone
Modifications at the MLH1 Promoter
Our previous work demonstrated that hypoxia induces short-
term, reversible downregulation of MLH1 via increased binding
of repressive Max/Mad1 and Max/Mnt complexes at the
proximal promoter of theMLH1 gene. To test if these repressive
complexes are also required for hypoxia-induced epigenetic
modifications at the MLH1 promoter, we established an
SW480-derived cell line with stable shRNA-mediated knock-
down of Max, SW480Maxsh-551 (Figure S8A). ChIP assays
were performed following exposure of SW480 Maxsh and
the control cell line, SW480GFPsh, to normoxia or hypoxia.
We found that knockdown of Max had no effect on hypoxia-
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Figure 6. LSD1 and CoREST Knockdown
Prevents MLH1 Promoter Remethylation
after Cessation of 5-aza-dC Treatment in
RKO Cells
RKO GFPsh, RKO LSD1sh, and RKO CoRESTsh
cells were treated with 5-aza-dC at 5 mm for
8 days. Then cells were released from 5-aza-dC by
placement in standard culture medium for 20 or 30
additional days. Real-time PCR to quantify DNA
methylation levels at MLH1 promoter was per-
formed using the MethyLight assay. PMR value
was used to quantify the methylation levels at
MLH1 promoter with error bars based on SEs
calculated from three replicates.
(A) MethyLight analysis of DNA methylation levels
in the MLH1 promoter in RKO-GFPsh cells
immediately after 5-aza-dC treatment (indicated
as D8), 20 days posttreatment (indicated as R20),
or 30 days posttreatment (indicated as R30).
(B)MethyLight analysis ofDNAmethylation levelsat
theMLH1promoter inRKO-LSD1shcells as above.
(C) MethyLight analysis of DNA methylation levels
at the MLH1 promoter in RKO-CoRESTsh cells.
(D) Graphical summary of the data in (A), (B),
and (C).(Figure S8B). Hence, whereas Max/Mad1 and Max/Mnt com-
plexes may mediate short-term, transient repression of MLH1,
they are not needed to mediate the histone modifications that
mark the locus for long-term silencing, a process that instead de-
pends on LSD1/CoREST. Hence, in the case of hypoxia and
regulation of MLH1, short-term, reversible repression and long-
term, durable silencing depend on separate pathways.
DISCUSSION
In this work, we show that hypoxia induces MLH1 silencing
through an orchestrated pattern of epigenetic modulation. Using
a reporter construct with the MLH1 promoter driving selectable
TK and BlastR genes, we established that hypoxia leads to
silencing of the MLH1 promoter and determined that the H3K4
demethylase, LSD1, is required for this process. The silencing
was seen to persist even after the cells were no longer in hypoxic
conditions, demonstrating durable, long-term epigenetic change
produced by exposure to hypoxic stress.
Mechanistically, we further show that the hypoxia causes
H3K4 demethylation at theMLH1 promoter via the H3K4 deme-510 Cell Reports 8, 501–513, July 24, 2014 ª2014 The Authorsthylases, LSD1 and PLU-1. We also show
that LSD1 and CoREST are required
for the resilencing of the endogenous
MLH1 promoter in RKO cells that occurs
following transient reactivation by 5-aza-
dC treatment. These results point to the
LSD1/CoREST complex as a possible
therapeutic target to inhibit the silencing
and/or resilencing of MLH1 and possibly
other tumor suppressor genes.
The finding that hypoxia promotes
silencing of the MLH1 promoter extendsour previous work showing that hypoxia drives epigenetic
silencing of BRCA1 (Lu et al., 2011). In the BRCA1 work, we
showed that silencing of the promoter could be induced by hyp-
oxia and that this couldbepreventedby treatment of thecellswith
the HDAC inhibitor, TSA (Lu et al., 2011). However, we had not
determined the histone-modifying factors that were necessary
to bring about the silencing. Here, we have identified LSD1 and
CoREST as the key factors required forMLH1 silencing.
In earlier work, we also identified the hypoxic tumor microen-
vironment as a driver of genetic instability (Bindra and Glazer,
2005; Reynolds et al., 1996; Yuan and Glazer, 1998). As one
mechanism for this effect, we determined that hypoxia causes
transient transcriptional downregulation of the MMR pathway
by provoking a shift in MLH1 promoter occupancy from acti-
vating c-Myc/Max to repressive Mad1/Max and Mnt/Max com-
plexes (Bindra and Glazer, 2007a). We now provide another
mechanism for hypoxia-induced genetic instability by directly
linking hypoxia with epigenetic regulation and durable long-
term silencing of MLH1.
More broadly, the results also suggest the possibility that
hypoxia may play a central role in epigenetic silencing not
only of MLH1 but also of other important tumor suppressor
genes that contribute to human cancers, such as p16, VHL,
or IL-2Rg (Baylin and Ohm, 2006; Jones and Baylin, 2007).
Our results may therefore provide new mechanistic insights
to suggest yet another role for hypoxia in cancer progression:
the induction of durable epigenetic change causing gene
silencing and consequent inactivation of critical tumor suppres-
sor pathways.
Because tumor hypoxia is a dynamic process, with fluctuating
regions of acute and chronic hypoxia reflecting a range of
vascular abnormalities and perfusion defects, the impact of hyp-
oxia on both the genome and epigenome of malignant cells can
be profound in its scope. This highlights hypoxia as a major fac-
tor in generating tumor heterogeneity, a phenomenon that
threatens to confound efforts at personalized medicine and the
development of targeted therapies.
LSD1 was one of the first histone demethylases identified (Shi
et al., 2004) and has been implicated in many cellular processes
(Forneris et al., 2008; Wang et al., 2007). Here, we have identified
a critical role for LSD1 in hypoxia-induced MLH1 silencing and
in resilencing following transient reactivation (by 5-aza-dC treat-
ment) in RKO cells. However, we found that knockdown of LSD1,
by itself, is not sufficient to reactivate the silenced MLH1 allele
in RKO cells, most likely because DNA methylation persists
and retains repressive complexes at the promoter.
Nonetheless, our work does provide a link between the LSD1/
CoREST and DNA methylation. Our results show that knock-
down of LSD1 or CoREST not only blocks H3K4 demethylation
at the MLH1 promoter but also blocks promoter DNA methyl-
ation after cessation of 5-aza-dC exposure. These results are
consistent with previous studies showing that H3K4 methylation
status plays an important role in preventing the establishment of
DNAmethylation (Ooi et al., 2007). This is also in keepingwith the
observations that LSD1 and the related demethylase, LSD2, are
important in maintaining global DNA methylation (Wang et al.,
2009) and in establishing maternal DNA genomic imprints
(Ciccone et al., 2009), respectively.
As knowledge of the cancer epigenome accumulates, there is
increasing interest in the development of epigenetic therapy for
cancer treatment. The DNA methyltransferase inhibitors, aza-
citidine and decitabine, and the HDAC inhibitor, vorinostat, are
already in clinical use. It has been suggested that the success
of such agents may lie with their ability to reactivate silenced
genes over long periods of time; however, after demethylation
and activation by 5-aza-dC treatment, many genes eventually re-
turn to a silenced state once the agent is removed (McGarvey
et al., 2006). One approach to prevent this is the use of a combi-
nation of DNMT and HDAC inhibitors (Gore et al., 2006; Moss-
man and Scott, 2011). Our work suggests that targeting LSD1
may represent another promising approach that could be used
alone or in combination with other such agents.
Several studies have reported overexpression of LSD1 in a
number of human cancers (Hayami et al., 2011; Kahl et al.,
2006), and LSD1 inhibitors have shown anticancer activity in pre-
clinical studies (Schenk et al., 2012; Willmann et al., 2012). Our
work demonstrating the role of LSD1/CoREST inMLH1 silencing
provides a further rationale to support the use of LSD1 inhibitors
in cancer therapy and suggests that cancers with overexpres-sion of LSD1 may be particularly prone to tumor suppressor
gene silencing.
In the particular case ofMLH1, prevention of silencing or reac-
tivation of a silenced allele would not only serve to suppress ge-
netic instability but also to restore the proapoptotic role of MLH1
in the DNA-damage response because cells deficient in MLH1
show a damage-tolerance phenotype (Buermeyer et al., 1999;
Meyers et al., 2001) and are resistant to cisplatin and temozolo-
mide, among others (Aebi et al., 1996; Drummond et al., 1996;
Francia et al., 2005). Hence, a pharmacologic strategy to inhibit
or reverse MLH1 silencing would be a valuable tool to render
cancer cells more sensitive to conventional chemotherapy.
EXPERIMENTAL PROCEDURES
Cells
HeLa,MCF-7, RKO, and SW480 cells were obtained from the ATCC and grown
according to the supplier’s instructions.
Constructs
Lentivirus vectors for shRNAs against KDM5A RBP2-sh-1 and RBP2-sh-3 and
control vector LLP were obtained from Dr. Marie Classon (Massachusetts
General Hospital). Lentivirus shRNA vectors for LSD1 knockdown were ob-
tained from Sigma-Aldrich (LSD1-1: TRCN0000046068). The lentivirus shRNA
vector for PLU-1 was obtained from Dr. Qin Yan (Yale University). Lentivirus
shRNA vectors for CoREST knockdown were obtained from Sigma-Aldrich
(CoREST: TRCN0000128260). The MLH1-TK-BlastR construct was produced
by cloning the human 1.7 kb MLH1 promoter into NheI pDisplay TK-BlastR
vector (Palakurthy et al., 2009).
Hypoxia
For severe hypoxia, cells weremaintained in culture under a continuous flow of
a humidified mixture of 95% N2 and 5% CO2 gas certified to <10 ppm O2 for
48 hr at 37C as previously described by Reynolds et al. (1996). For moderate
hypoxia (1% O2), an incubator was equipped with a PRO-OX 710 sensor
(Biospherix) to regulate the flow of 100% N2 at low pressure (<25 lb/in
2) in
order to achieve a constant O2 concentration within the entire incubator for
the indicated times. The CO2 level was maintained at 5% using an internal
CO2-regulation system.
ChIP Assays
ChIP assays were performed as described (Bindra and Glazer, 2007a). The
primer sequences for the MLH1 promoter have been reported (Bindra and
Glazer, 2007a). Antibodies used for ChIP assays are listed in Supplemental
Experimental Procedures.
Assays for MLH1 Promoter Silencing
RKO cells were transfected by Lipofectamine 2000 with 12 mg of MLH1-
TK-BlastR plasmid, and subclones stably expressing the TK and BlastR genes
(designated RKO MLH1-TK-BlastR) were established by selection first with
medium containing 1.5 mg/ml puromycin and 1 week later with medium con-
taining 10 mg/ml blasticidin. The RKO MLH1-TK-BlastR cells were then tested
for sensitivity to GCV to confirm the functional expression of the full MLH1-
TK-BlastR cassette.
To test the impact of hypoxia on silencing of theMLH1 promoter in the RKO
MLH1-TK-BlastR cells, cells were plated under 1%O2 (or normoxic conditions)
for 15, 25, or 35 days with passage once or twice per week. Cells at 100,000
cells per 100 mm dish were then subject to selection in presence of
10 mg/ml GCV. Colonies formed were counted for each condition tested and
normalized to plating efficiencies.
To measure reactivation of the MLH1 promoter in the silenced MLH1-TK-
BlastR cassette by 5-aza-dC treatment, selected clones containing silenced
MLH1 promoters (GCV-resistant subclones of the RKOMLH1-TK-BlastR cells)
were incubated inmedium containing either DMSO, 0.2 mM5-aza-dC or 0.3mM
5-aza-dC for 48 hr to inhibit DNA methylation. The cells were then plated inCell Reports 8, 501–513, July 24, 2014 ª2014 The Authors 511
100 mm dishes and the next day were exposed to medium containing either
10 mg/ml GCV or 10 mg/ml blasticidin to quantify cells that had regained TK
or BlastR expression. Silencing or reactivation frequencies were calculated
by dividing the number of clones growing under selection by the effective
number of cells plated (as determined by cloning efficiency).
Western Blots
Cells were lysed in RIPA buffer (25 mM Tris$HCl [pH 7.6], 150 mM NaCl, 1%
Igepal CA-630, 1% sodium deoxycholate, and 0.1% SDS) with protease inhib-
itor cocktail (Clontech Laboratories). The primary antibodies used for western
blotting are listed in Supplemental Experimental Procedures.
Analysis of DNA Methylation
Real-time PCR (MethyLight) was used for quantitative DNA methylation anal-
ysis (Eads et al., 2000). It is based on bisulfite-induced conversion of unmethy-
lated C into U, leaving methylated C intact. Bisulfite conversion was performed
using the EpiTect Bisufite Kit (QIAGEN). Two sets of primers and probes, de-
signed specifically to assay bisulfite-converted DNA, were used: a methylated
set for MLH1 gene, and a reference set, COL2A1 (the collagen 2A1 gene),
to normalize the amount of input bisulfite DNA (Pe´rez-Carbonell et al., 2010).
After bisulfite conversion, genomic DNA was amplified by fluorescence-
based, real-time quantitative PCR. PMR (percentage of fully methylated refer-
ence) value was used to calculate the amount of methylated DNA at theMLH1
promoter. The PMR calculation method is presented in Supplemental Experi-
mental Procedures.
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